



Drug Interaction Modeling and Visualization in **R** with **drugCombo**

Maxim Nazarov – *Open Analytics, Belgium*

Nele Goeyvaerts, Luc Bijmens – *Janssen Pharmaceutica, Belgium*

NCS2018 – October 3, 2018

drugCombo: R package for drug interaction (synergy/antagonism) analysis

Drug interaction

- Two (or more) drugs applied in combination
 - “Drugs work together” → **synergy**
 - “Drugs work against each other” → **antagonism**



Modeling

- We extend Harbron (2010) approach based on Loewe (1953) additivity model: estimate interaction index τ with

$$\tau < 1 \rightarrow \text{synergy}, \quad \tau = 1 \rightarrow \text{additivity}, \quad \tau > 1 \rightarrow \text{antagonism}$$


R package

- Freely available on CRAN: <https://cran.r-project.org/package=drugCombo>

drugCombo — Workflow

1. Monotherapy curve fitting
2. Combination model fitting
3. Model selection
4. Interaction index (τ) estimation

Summary and visualization throughout all stages



3D plot of the τ estimates

Thank you!

Give it a try

```
install.packages("drugCombo")  
vignette("userGuide", package = "drugCombo")
```

→

Get in touch

- maxim.nazarov@openanalytics.eu
- ngoeyvae@its.jnj.com

References

Harbron, Chris. 2010. "A Flexible Unified Approach to the Analysis of Pre-Clinical Combination Studies." *Statistics in Medicine* 29 (16). Wiley Online Library: 1746–56.

Loewe, S. 1953. "The Problem of Synergism and Antagonism of Combined Drugs." *Arzneimittelforschung* 3: 285–90.

<https://cran.r-project.org/package=drugCombo>

Drug interaction modeling based on Loewe additivity following Harbron's approach

Maxim Nazarov and Nele Goeyvaerts

June 15, 2018

- Introduction and Methods
 - 1-stage versus 2-stage estimation
 - Study design and data format
- Monotherapy Fitting
- Tau Estimation
 - Tau models
 - Pre-defined models
 - Model formula
- fitModel function
 - Convergence issues
- Diagnostic plots
- Tau graphical display
- Model Selection
- References

This vignette provides an overview of the `drugCombo` R package functionality and capabilities.

Introduction and Methods

Combinations of different biological active agents are of interest in several fields and often provide therapeutic advantages over single agents. Drug combinations are generally described as being synergistic or antagonistic. The Loewe additivity model (Loewe 1953) is one of the most commonly used models to quantify a zero-interactive state for the combination of two drugs:

$$\frac{d_1}{D_1} + \frac{d_2}{D_2} \begin{cases} = 1, & \text{additivity} \\ < 1, & \text{synergy} \\ > 1, & \text{antagonism} \end{cases}$$

where d_1 and d_2 represent the doses of the two compounds that in combination produce an effect y , and D_1 and D_2 represent the doses of the two compounds that produce the same effect y when given as a monotherapy.

Harbron (2010) introduced a flexible framework to assess in vitro synergy by fitting a hierarchy of interaction